Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111:4039–4047.
   PubMed Web of Science ®Google Scholar
• Pozzi S, Marcheselli L, Bari A, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. 2013;163:40–46.
   PubMed Web of Science ®Google Scholar
• Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma. 2012;53:632–634.
   PubMed Web of Science ®Google Scholar
• Mele G, Spina A, Guaragna G, et al. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma. Leuk Lymphoma. 2014;55:1191–1193.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Offidani M, Patriarca F, et al. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. Leuk Lymphoma. 2015;56:559–567.
   PubMed Web of Science ®Google Scholar
• Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. Int J Lab Hematol. 2014;36:20–28.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol. 2011;155:632–634.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol. 2012;138:1405–1412.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010;10:21–27.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Gaul L, Mandl-Weber S, Baumann P, et al. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 2008;134:245–253.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Rozanski M Goldschmidt H. et al. East German Study Group of Haematology and Oncology (OSHO). Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008;143:191–200.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119:4608–4613.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br J Haematol. 2013;162:202–209.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Krishnan A LaPlant B, et al. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. Am J Hematol. 2015;90:1106–1110.
   PubMed Web of Science ®Google Scholar
• Schey S, Brown SR, Tillotson AL, et al. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015;170:336–348.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013;139:499–508.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123:985–991.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3:e162.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160:321–330.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, San Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1147.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Bethesda (MD): Cancer Therapy Evaluation Program; 2010.
   Google Scholar
• Cheson BD, Brugger W, Damaj G, et al. Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel – an update. Leuk Lymphoma. 2015;23:1–17.
   Google Scholar
• Rodon P, Hulin C Pegourie B, et al. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica. 2015;100:e56–e59.
   PubMed Web of Science ®Google Scholar